One in 25 patients underwent surgery in the first year after PCI, requiring DAPT interruption, frequently recommended by non-cardiologists and most commonly due to minor surgery.
Background: CYP2C19 gene polymorphisms affect clopidogrel metabolism resulting in variability in response. We sought to assess the frequency of CYP2C19 variants and association of stent thrombosis (ST) in a series of individuals undergoing percutaneous coronary intervention (PCI). Methods: A case-control study of 10 patients with stent thrombosis and 38 patients were routinely tested for CYP2C19 gene variants using the Verigene (Nanosphere Inc, Illinois) and iPLEX assays (Sequenom Inc, San Diego). Patients were genotyped for three single-nucleotide polymorphisms of the CYP2C19 alleles (*2, *3, *17). Results: Of 48 patients undergoing gene testing 31(65%, 95%CI: 49%, 78%) carried a loss-of-function (LOF) CYP2C19 allele. Call rate and concordance was 100% between the two assays. PCI was performed for acute coronary syndrome in 73% of patients. In patients with a variant allele, 17(55%) were *2, 11 (35%) were *17, and 3(10%) were both *2 and *17. No patient had the CYP2C19*3 variant. LOF alleles were present in 80% of patients with ST compared to 61% in patients without ST (OR¼2.6, 95%CI: 0.5, 14) . Five patients with a LOF allele, had either a clopidogrel dose increase or were changed to prasugrel, with no in-stent thrombosis in these patients. Conclusions: Carriage of a LOF CYP2C19 allele is associated with a higher odds ratio of in-stent thrombosis in patients on standard dose clopidogrel, highlighting the need for routine gene testing. Patients with a LOF allele should have alteration of P2Y12 inhibitor therapy with either a higher dose of clopidogrel or a switch to prasugrel or ticagrelor.
TCT-504
Bleeding risk in Acute Coronary Syndrome submitted to PCI with new oral antiplatelet agents Figure 1 ).
Conclusions:
Experience across operators suggests equipoise in the selection of DAPT duration after peripheral artery intervention, with longer prescription duration selected for patients with preexisting coronary artery disease.
TCT-506
Comparison Background: Recent trials indicate that both Ticagrelor and Prasugrel are superior to Clopidogrel in preventing cardiovascular events. However, as to date, no trials have been conducted comparing these drugs directly. We compared 30-day mortality in patients with STEMI receiving Ticagrelor or Prasugrel. Methods: This retrospective study included 1069 consecutive STEMI-patients in the Catharina Hospital, Eindhoven area, The Netherlands. From April 2012 until April 2013, patients received Prasugrel loading (60mg) and maintenance dose (patients older than 75 years or weighing less than 60 kg were given Clopidogrel). From April 2013 onward, they received Ticagrelor loading (180mg) and maintenance dose. Death was defined as death from any cause within 30 days after primary PCI. Binary logistic regression was used for comparison of anti-platelet strategies. Results: No patients were lost to follow-up. In the Ticagrelor group 28 out of 524 patients (5.3%) died within 30 days after PCI, as compared to 21 out of 545 patients (3.9%) in the 'Prasugrel/Clopidogrel' group (OR, 1.4;95% CI, 0.79 to 2.5; p¼0.2).
Analysis of the Ticagrelor group compared with Prasugrel alone ((n¼305) by excluding Clopidogrel-treated patients) showed a 2.3% mortality in the Prasugrel group (OR, 2.4;95% CI, 1.04 to 5.57; p¼0.04). However, after adjusting for age, no significant difference was found between Ticagrelor and Prasugrel treated patients (OR, 1.5; 95% CI 0.61 to 3.6; p¼0.4).
Conclusions:
We found no significant difference in 30-day mortality in STEMIpatients treated with Ticagrelor or Prasugrel in a large, retrospective, single-centre study. Background: Renal Artery Aneurysms (RAAs) can be surgically treated but due to high risk, endovascular procedures have been proposed (coils, graft...). All these techniques have some drawbacks, potential complications and contraindications. We propose a new technique: the Multilayer Flow Modulator (MFM*), a self expandable. Methods: This MFM* is a 3D braided tube made of several interconnected layers without any covering. Our earliest tests, in vitro (theorical simulation computerized Fluid dynamics, Molecular Modelization) & in vivo. demonstrate that this MFM* reduces the velocity in the aneurismal sac up to 90% by modifying the hemodynamic conditions.. A saccular aneurysm (A.) without collateral branch will thrombose quickly. If a collateral branch is present the flow is directed towards this branch leading to shrinkage of the aneurysm. In fusiform A. the flow is laminated, the vortexes eliminated, eliminating the risk of rupture. Animal experiments show excellent results. Moreover, as demonstrated in animal and human studies this MFM preserves the collateral branches and increases the flow in them, allowing the possibility to cover any artery without compromising the flow. Results: 8 RAAs (right:5, left: 3) in 8 pts (male: 3) mean age 58 y. treated with MFM* 6 pts had atheromatous disease, 2 a fibromuscular dysplasia. One pt had a solitary kidney. All these pts had hypertension. 10 MFM*(⌀: 5 to 6 mm, length 30 to 60 mm) loaded in a 6 F sheath implanted by femoral approach through 8 F guiding catheter. These stents covered major renal branches without compromising the flow. Technical success: 100%. No complications. Immediately: important reduction of the velocities inside the aneurismal sac. 6 to 36 month follow up will be presented. All aneurysms thrombosed with diameter reduction in some pts. The thrombosis could take several weeks depending on the importance of collateral branches. All the side branches remain patent.
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